ALX ONCOLOGY HOLDINGS INC (ALXO) SEC Filings

ALX Oncology Holdings Inc. (ALXO) reported that officer Shelly Wong, SVP, Finance and CAO, sold 573 shares of Common Stock on 2026-08-17 at $1.93 per share. According to the disclosure, the shares were sold to satisfy tax obligations arising from the vesting of restricted stock units. After this transaction, Wong directly holds 87,828 shares of ALXO common stock.

ALX Oncology Holdings Inc. received an amended Schedule 13G from TCG Crossover investment entities and Chen Yu updating their reported ownership of the company’s common stock. TCG Crossover Fund II, L.P. and its general partner TCG Crossover GP II, LLC each report beneficial ownership of 2,827,739 shares, or 2.1% of the outstanding common stock, with shared voting and dispositive power over these shares. TCG Crossover Fund III, L.P. and TCG Crossover GP III, LLC each report beneficial ownership of 2,827,748 shares, or 2.1% of the class, also on a shared-power basis.

Chen Yu, as sole managing member of both TCG Crossover GP II and TCG Crossover GP III, may be deemed to beneficially own an aggregate 5,655,487 shares, representing 4.2% of ALX Oncology’s common stock, based on 134,562,917 shares outstanding as of May 1, 2026. The reporting persons state that they disclaim beneficial ownership of the securities except to the extent of their pecuniary interest and also note that they are reporting ownership of 5 percent or less of the class.

ALX Oncology Holdings Inc. reported unaudited results for the quarter ended June 30, 2026, as it continues to develop its evorpacept and ALX2004 oncology programs. The company has not realized product revenues from its planned principal operations and remains focused on clinical trials in HER2‑positive and EGFR‑expressing cancers.

For the three months ended June 30, 2026, net loss was $17,971 thousand, or $(0.13) per share, compared with $25,949 thousand, or $(0.49) per share, a year earlier. Total operating expenses were $18,033 thousand, driven mainly by research and development of $13,138 thousand and general and administrative expense of $5,133 thousand, and included a $238 thousand lease termination gain versus a $3,175 thousand impairment charge in 2025.

Liquidity increased significantly. Cash, cash equivalents and investments were $153.4 million as of June 30, 2026, compared with $48.3 million at December 31, 2025, reflecting a February 2026 registered equity offering that generated approximately $140.4 million in net proceeds and a new $10.0 million HSBC term loan that refinanced prior debt. Net cash used in operating activities was $34,705 thousand for the first half of 2026, and management states existing capital resources are expected to fund projected operating requirements for at least the next twelve months after the financial statements are issued.

ALX Oncology Holdings Inc. reported second quarter 2026 results, with GAAP net loss of $18.0 million for the three months ended June 30, 2026, compared with $25.9 million a year earlier. Cash, cash equivalents and investments were $153.4 million as of June 30, 2026, which the company expects will fund planned operations through the first half of 2028.

Research and development expenses were $13.1 million, down from $18.0 million, reflecting lower legacy trial costs while continuing to invest in the Phase 2 ASPEN-09-Breast evorpacept trial and the Phase 1 ALX2004 study. Non-GAAP net loss was $14.3 million, compared with $20.6 million in the prior-year quarter.

The company highlighted progress in its oncology pipeline, including biomarker-driven evorpacept data presented at ESMO Breast Cancer 2026 and ongoing enrollment in ASPEN-09-Breast with topline data from 80 patients expected in mid-2027. Enrollment continues in the Phase 1 ALX2004 antibody-drug conjugate trial in EGFR-expressing solid tumors, with initial safety data expected in the second half of 2026. ALX Oncology refinanced $10 million of existing debt and entered into a secured multi-tranche term loan facility of up to $50 million, including the ability to draw an additional $20 million through June 2028, and appointed Scott Garland as Chairman and Michael Listgarten as General Counsel.

BlackRock, Inc. filed a Schedule 13G reporting passive ownership of common stock of ALX Oncology Holdings Inc. BlackRock and its reporting business units beneficially own 7,327,850 ALXO shares, representing 5.4% of the outstanding common stock as of the filing.

BlackRock reports sole voting power over 7,231,560 shares and sole dispositive power over 7,327,850 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of ALXO’s outstanding common shares.

ALX Oncology Holdings SVP Shelly Wong reported an open-market sale of 1,404 shares of Common Stock at a weighted average price of $2.04 per share. According to the filing, the shares were sold to satisfy her tax obligations related to vesting of restricted stock units.

After this transaction, she directly holds 88,401 shares, which includes 3,000 shares acquired under the company’s employee stock purchase plan on June 30, 2026.

ALX Oncology Holdings Inc. reported a planned leadership transition at the board level. Corey Goodman, Ph.D., co-founder and long-time Chairman, resigned from the board and all its committees effective June 29, 2026, citing personal reasons and no disagreements with the company.

The board appointed existing independent director Scott Garland as Chairman effective the same date and named Michael Listgarten as General Counsel. Committee memberships were updated, with Rekha Hemrajani chairing Audit, Chris Takimoto chairing Compensation, and Daniel J. Curran chairing Corporate Governance and Nominating, reflecting a refreshed governance structure.

ALX Oncology Holdings Inc. entered into a new secured multi-tranche term loan facility of up to $50,000,000 with HSBC Ventures USA Inc. on June 25, 2026. The company drew $10,000,000 at closing to refinance its prior Oxford Finance and Silicon Valley Bank loan and pay fees, with remaining proceeds available for general corporate purposes.

An additional $20,000,000 is available to draw through June 30, 2028, with a further $10,000,000 tied to achieving positive data milestones in the Phase 2 ASPEN-09 study of Evorpacept and positive safety data in the Phase 1 study of ALX2004. A final $10,000,000 may be provided at the lender’s sole discretion.

The loans mature on June 1, 2030 and bear a floating interest rate equal to the greater of the Prime Rate or 6.0%, with amortization beginning July 1, 2028 or, if an Interest Only Milestone Event occurs, July 1, 2029. The facility is secured by substantially all assets (with a negative pledge on intellectual property) and includes customary covenants and events of default that could accelerate repayment if breached.

ALX Oncology Holdings Inc. held its Annual Meeting of stockholders on June 10, 2026. Stockholders elected Class II directors Daniel Curran, M.D., Rekha Hemrajani, and Chris Takimoto, M.D., Ph.D., F.A.C.P. to serve until the 2029 annual meeting, each continuing until a successor is elected and qualified.

Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers, as described in the proxy statement. In addition, they ratified the appointment of KPMG LLP as ALX Oncology’s independent registered public accounting firm for the fiscal year ending December 31, 2026.